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analysis aims to give guidance in decision situations where benefits do nonefit–risk analysis in the area of food and nutrition by learning from othe
s the final stage of the project, in which commonalities and differences in ben
fied between the Food and Nutrition field and other fields, namely Medicine
mental Health, Economics and Marketing–Finance, and Consumer Perceptio
characterized for benefit–risk analysis in Food and Nutrition. Integrated ben
d Nutrition may advance in the following ways: Increased engagement an
sessors, managers, and stakeholders; more pragmatic problem-oriented fram
g some risk; pre- and post-market analysis; explicit communication of th
and output; more human (dose–response) data and more efficient use o
opulations based on physiology; explicit consideration of value judgmen
of multiple benefits and risks from multiple domains; explicit recognitio
eliefs, opinions, views, perceptions, and attitudes on behaviour; and segmen
ehaviour; the opportunities proposed here do not provide ultimate solution
on of issues to be taken account of in developing methods, tools, practices an
the regulatory context, for benefit–risk analysis in Food and Nutrition an
portunities will now need to be explored further and incorporated into ben
. If accepted, incorporation of these opportunities will also involve a paradigm
benefit–risk analysis towards conceiving the analysis as a process of creatin
ll stakeholders.
 2011 Elsevier Ltd. All rights reserve
1. Introduction and approach
Benefit–risk analysis of Food and Nutrition is developing fas
Benefit–risk analysis aims to give guidance in decision situation
where both benefits and risks have been identified; when th
benefits do not clearly prevail over the risks, explicit weighing o
benefits and risks is indicated. Benefit–risk analysis can be see
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mmunication of integrated benefits and risks, analogous to the
mmon contemporary risk analysis paradigm (Fig. 1) (WHO/
O, 1995).
Benefit–risk assessment of Food and Nutrition comprises a sci-
ce-based process intended to qualitatively or quantitatively esti-
ate the benefits and risks for humans following exposure (or lack
exposure) to a particular food or food component and includes
e potential to integrate them into comparable measures. Bene-
–risk management entails the process of weighing policy alterna-
es in light of the results of benefit–risk assessment and other
levant information. Benefit–risk communication covers the inter-
tive exchange of information and science-based opinions con-
rning benefits and risks among assessors, managers, consumers
d other stakeholders.
The scope of Food and Nutrition risk assessment is fairly well
tablished (Renwick et al., 2003); it deals with the assessment
adverse health effects caused by physical or chemical agents,
curring naturally in foods or as environmental contaminants,
resulting from food preparation or manufacturing processes.
wever, in the benefit–risk context, the scope of benefit-assess-
ent is a point of discussion. A beneficial effect can be looked at
the reverse of an adverse effect (WHO, 1994), i.e. a physical or
her change within a person that improves functional capacity
the capacity to deal with stress or that decreases susceptibility
harmful effects. This can be measured as prevention of disease,
. reduction of risk, but currently it is difficult to measure benefits
rectly, at an early stage or as an ‘above-normal’ capacity. Cases
ere the benefit is obvious but where different risks are involved
severity and mechanism) could also be taken under the wing of
nefit–risk analysis. Benefit–risk analysis presents up-to-date
owledge in a dynamic public health process, aimed at optimiza-
n, i.e. looking for ways to maximize benefits while minimizing
k.
In recent years, many projects have done significant work to
entify the possibilities and difficulties of benefit–risk analysis
the Food and Nutrition field (Tijhuis et al., 2011). Much progress
s already been made, but benefit–risk thinking and practise have
t yet become commonly established. Therefore, for further
velopment, the field of Food and Nutrition could benefit from
king beyond its borders and learning from other fields of re-
arch (and possibly also vice versa) and this is the explicit goal
BEPRARIBEAN project (http://en.opasnet.org/w/Bepraribean)
erhagen et al., 2011). To serve this goal, we recently compiled re-
ws covering the state of the art in benefit–risk analysis for Food
d Nutrition (Tijhuis et al., 2011) and five other fields: Medicines
teijn et al., 2011), Food Microbiology (Magnússon et al., 2011),
vironmental Health (Pohjola et al., 2011a), Economics and Mar-
ting–Finance (Kalogeras et al., 2011) and Consumer Perception





(interactive exchange of 
information and opinions
among all stakeholders)
. 1. Contemporary benefit–risk analysis framework. Based on the risk analysis
mework by WHO/FAO (1995).ease cite this article in press as: Tijhuis, M.J., et al. Looking beyond borders: Inte
utrition. Food Chem. Toxicol. (2011), doi:10.1016/j.fct.2011.11.044searchers from within the respective fields and were contributed
by the researchers from the other fields. Summaries of the key
ues from the reviews and a summary of the contemporary reg-
atory context for Food and Nutrition management and assess-
ent are presented in Section 2.
In Section 3, the focus is on identifying how the benefit–risk ap-
oaches in the different areas compare to and differ from the ben-
t–risk approaches in the area of food and nutrition. In order to
emplify the (combined) perspectives and approaches from with-
the different areas, we include an example of a case: the effects
replacing current animal protein sources by more sustainable
etary protein sources. This topic was considered suitable because
is inherently multi-disciplinary and currently of global interest.
is example is meant as an illustration and does not aim to be a
nclusive analysis.
From this, in Section 4, we aim to identify opportunities for fur-
er development of benefit–risk analysis in food and nutrition.
In Section 5, we sum up the main points of this paper, and the
ole BEPRARIBEAN project, and indicate some implications that
ese points will or may have for Food and Nutrition benefit–risk
alysis in the future.ntext for Food and Nutrition
In 2.1–2.6 we summarize the key issues from the 6 state of the
t reviews: Food and Nutrition (Tijhuis et al., 2011), Medicines
teijn et al., 2011), Food Microbiology (Magnússon et al., 2011),
vironmental Health (Pohjola et al., 2011a), Economics and
arketing–Finance (Kalogeras et al., 2011) and Consumer Percep-
n (Ueland et al., 2011). They are complemented in 2.7 with a
ort overview of the contemporary regulatory context for Food
d Nutrition management and assessment in the European Union.
. Benefit–risk analysis in Food and Nutrition (Tijhuis et al., 2011)
This paper addresses the three components of benefit–risk anal-
is, but focuses on assessment. Benefit–risk assessment in Food
d Nutrition is geared to weigh the beneficial and adverse effects
ood or food component may have, in an integrated measure, in
der to make better-informed policy decisions regarding public
alth issues.
Historically, the assessments of risks and benefits have been
parate processes. In risk assessment, toxicology is the main con-
butor as the toxicological approach is demanded by regulation. Itd that division of this dose by appropriate safety factors defines
e ‘safe’ intake for the human population. Epidemiology plays a
inor role in risk assessment. Epidemiology describes associations
tween risk (or beneficial) factors and disease endpoints in hu-
ans. It has traditionally focussed more on relative than on abso-
te risks. Nutrition, as a science, uses a mixture of methodologies
d is involved in estimating risks specifically for nutrients and
her dietary factors. Benefit assessment for Food and Nutrition
newly developing in regulatory terms, but has been the subject
nutritional epidemiological research for a long time. Benefit
sessment is working on concepts such as whether reduction of
k of disease should be termed a benefit, whether a benefit can
measured as a state rising above the average health and in
ich time frame (short or long term), and how broad its scope
ould be. In nutrition, current interest is in ‘optimal’ food and
trient intake, implying knowledge of both intakes where risks
cur and intakes where benefits occur. In this, there is a scientific
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2 December 2011intake based on subgroups. In summary, the goal of risk assess
ment in food and nutrition is to reasonably guarantee absence o
an effect (risk) whereas the goal of benefit assessment is to reason
ably guarantee the presence of an effect (benefit). This distinctio
affects the assessment approach, the evaluation of the generate
data and the way these can be used. In both risk and benefit assess
ment, good dose–response data, i.e. with relevant intake levels an
suitable for the target population, are scarce. Better integration o
all underlying disciplines and an approach focussed more on hu
mans and continuous data is indicated.
Current approaches to bring benefit and risk assessment to
gether mirror the traditional risk assessment paradigm of hazar
identification, hazard characterization, exposure assessment an
risk characterization. A tiered approach is advocated, as this allow
for transparency, in-between consultancy with the benefit–ris
manager and the possibility of an early stop in the assessmen
and thus increased efficiency. There is agreement about the impor
tance of a good description of the benefit–risk question and th
uncertainties in its assessment. Benefit–risk comparison can b
qualitative and quantitative, with increasing data requirement
In a quantitative comparison, benefits and risks are expressed i
a common currency. Severity of disease can be taken into accoun
by attributing weights, e.g. using disability adjusted life year
(DALY’s). These integrated measures need to be accompanied b
at least (1) a description of the unintegrated benefits and risk
on subgroups and (2) data uncertainties. In the quantificatio
process, deterministic input may be substituted by probabilist
input; well-accepted methodology for probabilistic assessment
available.
Close communication, between and within benefit–risk asses
sors and managers, requires attention. In benefit–risk managemen
some risk will have to be considered acceptable in order to achiev
more benefits. Thus, current risk management will also need t
consider a shift from striving for zero risk towards explicit weigh
ing of risks and benefits in order to achieve an optimal outcom
The communication of benefits and risks to the public used to b
separate, but the impact of combined benefit–risk messages
being explored.
In conclusion, benefit–risk assessment is developing steadily i
the field of food and nutrition. General point of attention is th
communication between fellow scientists, managers and the gen
eral public. General strengths are the ability to systematicall
and transparently show the current knowledge and its gaps an
to provide what is likely the best answer to a question with a larg
potential impact on public health.
2.2. Benefit–risk analysis in Medicines (Luteijn et al., 2011)
Medicines can lead to significant health benefits. The healt
benefits come at the risk of potential adverse drug reactions. Sinc
the thalidomide disaster in the early 1960s, increased regulator
attention has been placed in the benefit–risk profiles of medicine
This key-event has lead to not only demands on safety demonstra
tion before registration of a medicine, but also to demands in re
gard to demonstration of efficacy, i.e. the effectiveness of
medicine under controlled conditions.
Benefit–risk assessment in medicine is highly regulated and ha
been developed for decennia. Benefit–risk assessment (and mon
toring) takes place both in the pre-registration and the post-regis
tration phase of a medicine. In the pre-registration phase, th
candidate medicine goes through a process of phase I–III trial
involving populations of increasing size and different aims and de
signs as discussed in the state of the art paper. These clinical tria
are conducted by the manufacturer and involve a considerabl
financial investment. Trials will only be continued if the manufac
turer feels the drug stands a chance to successfully gain marketinPlease cite this article in press as: Tijhuis, M.J., et al. Looking beyond borders
Nutrition. Food Chem. Toxicol. (2011), doi:10.1016/j.fct.2011.11.044authorization by sufficient proof of efficacy and safety. Data gath
ered by these clinical trials, reinforced by animal model data an
possible post-marketing experience with similar compounds, wi
provide the safety and efficacy data for the marketing authoriza
tion procedure. The pre-marketing clinical trials have bee
criticized for being designed for fast approval instead of the gener
ation of scientific knowledge. A number of mainly quantitativ
benefit–risk methods are employed during the pre marketin
phase, including ‘number needed to treat’ and ‘number needed t
harm’. Expert opinions play a big role in benefit–risk assessmen
of medicines, both pre-registration and post-registration. There
no standard protocol for analyzing the benefit–risk profile of
drug, after the manufacturer submits the clinical trial data, respon
sible authorities will take the evidence into account and form a
expert opinion on the registration submission. Both the benefit
(efficacy) and the risk (adverse drug reactions, ADRs) play a rol
in this expert opinion: larger benefits can justify larger risks. N
consensus has been reached on a standardized methodology fo
benefit–risk assessment in medicine registration. The Europea
Committee for Medicinal Products for Human Use recommend
the use of multiple types of mainly qualitative, benefit–risk meth
odology and argues that use of quantitative methodology can lea
to a misleading feeling of precision.
2.2.1. Pre-registration
The pre-registration clinical trials themselves suffer from
number of practical limitations; these include the small numbe
of subjects in clinical trials, a restricted population in terms o
age, gender and ethnicity, restricted co-medication and co-morbid
ity, a short duration of exposure and follow up and statistical prob
lems with assessing multiple outcomes. These problems ar
acknowledged by the responsible authorities. Because the clinica
trials take place in a controlled environment, situations of off-labe
use, drug–drug interactions and non-compliance will be limited t
theoretical consideration. Therefore, clinical trials will provid
information on the efficacy of a medicine, rather than effectivenes
of a medicine. Despite the differences between efficacy and effec
tiveness, efficacy will provide an indication of effectiveness of
drug. It should be realized there is no solution for the majority o
these problems. For example; it would be ethically unacceptabl
to conduct safety experiments in pregnant women. Experience i
this population will be limited to animal models and post-registra
tion data.
During the application process, a risk management program
will be submitted along with the clinical trial data, outlining ris
minimization and post marketing surveillance activities.
2.2.2. Post-registration
After registration, the benefit–risk profile of medicines will b
monitored by post-marketing surveillance. Pre-marketing know
edge on the benefit–risk profile of a medicine will be limited fo
reasons mentioned above. Post-marketing surveillance is con
ducted by responsible authorities, marketing authorization holder
and independent researchers in order to collect data on ADRs an
monitor the effectiveness of existing risk management activities. I
case a new ADR is discovered, responsible authorities can reasses
the benefit risk profile forming a new expert opinion. Informatio
discovered during post-marketing surveillance can lead to modifi
cation of marketing authorizations, risk management programs o
even suspension of marketing authorizations in the case of seriou
ADRs. Many recent developments and initiatives are currentl
ongoing in post-marketing surveillance, many of them involvin
large databases to collect information on ADRs. The more statistica
power, the better the investigators are able to detect ADRs. For th
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ace in Europe. Other problems include different legislation be-
een European countries.
A different type of benefit–risk assessment in the post-registra-
n phase is Health Technology Assessment (HTA). In HTA, the
alth impact and economic impact of a new health technology
e assessed using (economic) modelling techniques, usually in or-
r to be included in public formularies. The main challenge of HTA
to assess the trade-offs between financial investment and health
nefits. For this purpose, indexes such as QALY and DALY have
en developed. The trade-off between financial investment and
alth benefits is perceived as controversial by many. Marketing
thorizations have become less meaningful without reimburse-
ent (after a positive HTA assessment) in many countries. The
andate and methodology of HTA agencies differ between
untries.
The state of the art paper concluded that no ‘one size fits all’ ap-
oach is available for benefit–risk assessment in medicines.
oice of methodology depends on the context of the benefit–risk
sessment, including indication, patient groups and the stage of
e regulatory process. Also, use of multiple methodologies is
couraged due to each having its own specific strengths and
akness. Furthermore, improved cooperation between responsi-
authorities and HTA agencies can be of value in benefit–risk
sessment.
. Benefit–risk analysis in Food Microbiology (Magnússon et al.,
11)
Microorganisms, i.e. bacteria, fungi and viruses, are all constitu-
ts of our natural environment. The field of food microbiology
ncerns the multitude of microorganisms that inhabit and con-
minate our foods. Food and nutrition are essential for sustaining
man life. However, no food carries zero risk for microbiological
zards. The risk varies considerably depending on food types
d matrices. Some foods have a higher risk than others of contain-
g microbiological contaminants and pathogenic microorganisms
at can be hazardous to our health and well being. Furthermore,
nsumer sub-groups can be variably susceptible to foodborne
fections and intoxications; the elderly, young children and indi-
uals with underlying diseases being more at risk.
Food microbiology is largely focused on food safety and limiting
blic exposure to harmful foodborne pathogens. However, the
eat majority of microorganisms are harmless to our health and
any microorganisms are even important to various food produc-
n processes e.g. the making of cheese, wine, beer and bread.
icroorganisms are used in various ways for the benefits of hu-
ans e.g. through advances in medical technology, biotechnology,
riculture and in food processing, to name a few. Although micro-
ganisms can be seen as indirectly beneficial to human health
rough the above-mentioned activities, the human health conse-
ences of microorganisms in foods are often either neutral or ad-
rse. In food microbiology the reduction in human exposure to
odborne pathogens can commonly be regarded as the main pub-
health benefit. Probiotic microorganisms and the activities of
e gut microflora can be mentioned as an exception to this –
e effect of probiotics can be seen as directly beneficial to human
alth. It must be noted, however, that to date all such probiotic
alth claims have been refuted by the European Food Safety
thority (EFSA, http://www.efsa.europa.eu/en/topics/topic/arti-
13.htm); currently, there is lack of evidence for the direct bene-
ial effects as judged by EFSA’s criteria, but at the same time there
lack of evidence that beneficial effects do not exist.
Benefit–risk analysis is a relatively new and to-date largely
defined field of research within food microbiology. The bene-
–risk analysis approach is concerned with issues affecting public
alth and improving public health management based on theease cite this article in press as: Tijhuis, M.J., et al. Looking beyond borders: Inte
utrition. Food Chem. Toxicol. (2011), doi:10.1016/j.fct.2011.11.044lanced weighing of risks and benefits. From a food microbiolog-
l standpoint studies using methods that balance risks and/or
ks and benefits using composite metrics are scarce. Published
dies to date have mainly been intervention assessments or risk
mparison studies that apply risk assessment criteria for compar-
g the level of two individual risk factors – with the purpose of
entifying the most important health risks – commonly a chemi-
l risk and the benefits of reduced microbiological risk. The crite-
for the assessment of risks are well established within food
icrobiology (and are based on risk assessment criteria developed
thin toxicology), but at present the criteria for assessing positive
alth effects are not well defined.
A key issue in food microbiological benefit–risk analysis is how to
dress the assessment of benefits and the multidisciplinary discus-
n of how to aggregate risk and benefit estimates. The most
aightforward approach to be used for benefit–risk analysis in food
icrobiology could be envisioned to follow the tiered approach for
nefit–risk analysis formulated in the field of food and nutrition.
od microbiological benefit–risk analysis converges largely with
at of food and nutrition. In addition, it often involves the evalua-
n of chemical as well as microbiological risks and benefits.
Disability adjusted life years (DALY’s) have widely been opted
r as a metric of choice for ranking microbiological risk, including
odborne pathogens. It can be used as the single metric for assess-
g both microbiological and chemical hazards and could similarly
implemented for evaluating benefits. DALY’s have previously
en used for assessing the global burden of disease, injury and
k factors and currently the global burden of foodborne disease
being estimated using DALY’s (http://www.who.int/foodsafety/
odborne_disease/ferg/en/index3.html). Based on this extensive
oundwork, as food microbiology benefit–risk analysis goes,
LY’s are likely to be the common metric of choice, despite its
ortcomings.
In conclusion, the field of benefit–risk analysis in food microbi-
gy is in its infancy and the assessment criteria for benefits are
t well defined. Reduced pathogen risk can be seen as the princi-
l benefit regarding food microbiology while scientific data on di-
ct microbial benefits are lacking.
. Benefit–risk analysis in Environmental Health (Pohjola et al.,
11a)
The field of environmental health is very broad and involves sig-
ficant physico-chemical, biological, technological and social
mplexity. Consequently there is no single state-of-the-art ap-
oach, but a multitude of approaches to assess environmental
alth risks and benefits have been developed for different pur-
ses and contexts within the field. These approaches can be char-
terized e.g. as either regulatory or academic, depending on the
ntext of development and application for the approach, or rather
ditional or novel, depending on how strictly and narrowly the
sessment scope and procedure are determined by the approach.
In comparison to the traditional and regulatory approaches the
phasis among the more novel and academic approaches is on (a)
creased engagement between assessors, decision makers, and
keholders, (b) more pragmatic problem-oriented framing of
sessments, (c) integration of multiple benefits and risks from
ultiple domains, and (d) inclusion of values, alongside scientific
ts, in explicit consideration in assessment. These tendencies
n be considered as responses to the challenge of complexity
thin the field, but also as indications of the incapability of the
rrently established approaches to adequately address all aspects
this complexity. On the other hand, the all-embracing aims of
e novel academic approaches may also lead to lack of clarity in
mparison to the regulatory and traditional approaches, unless
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2 December 2011The key issues in benefit–risk analysis in environmental healt
are not so much related to the technical details of performing th
analysis, but rather to (i) the level of integration, and (ii) the per
spective to consider the relationship between assessment and th
use of its outcomes. The level of integration can range from pro
ducing health risk estimates for single substances to aggregation
weighing, and comparison of multiple benefits, risks, impact
and costs alongside explicit account of values of those concerned
Significant differences are also brought about by whether a
‘‘assessment push’’ or an ‘‘information need pull’’ perspective
adopted. The perspective largely defines what, how and why, is
sues are considered in an assessment.
In the ‘‘assessment push’’ perspective, the issue to be assessed
defined by those responsible for the assessment, and the focus o
assessment is to produce an objective estimate of the risk
benefits, etc. according to certain defined principles and mean
whatever the estimate may be used for. Approaches taking a
assessment push perspective thus also predetermine the possibl
levels of integration in terms of e.g. what phenomena are consid
ered, whether also benefits or costs are considered in addition t
risks, and what means of aggregation or comparison are used. I
the ‘‘information need pull’’ perspective the issue to be assessed
as well as the principles and means for its assessment, is formu
lated according to a specified practical need. The need thus deter
mines the suitable format of the assessment outcome, whic
further determines how the assessment should be made. Therefor
inclusion of all relevant issues, all levels of integration, and a
means of aggregation and comparison are, at least in principl
available for use as required to serve the need. Naturally, most o
the approaches to environmental health assessment fall some
where in between these extremes by incorporating aspects of bot
push and pull. However it can be identified that the regulatory an
the most traditional, simultaneously the currently most estab
lished, approaches clearly position themselves closer to the assess
ment push end of the continuum.
Challenges lie in the aggregation, weighing, and/or compariso
of multiple benefits and risks. For example: the use of DALY’
QALYs or euro’s as general aggregate measures, incommensurabi
ity of benefit estimates aiming for avoidance of false positives an
risk estimates aiming for avoidance of false negatives, and takin
account of perceived risks and benefits together with ‘‘scientificall
assessed’’ risk and benefit estimates.
In conclusion, probably most of all commonly known method
for benefit–risk analysis are applied among the various differen
approaches to environmental health assessment, but there is n
single view to dominate the whole broad field.
2.5. Benefit–risk analysis in Economics and Marketing–Finance
(Kalogeras et al., 2011)
Risk is a key component of economic behaviour. All market par
ticipants (e.g. investors, producers, consumers) accept a certai
level of risk as necessary to achieve certain benefits. There ar
many types of risk including price, production, financial, institu
tional, and individual human (e.g. health-related) risks. All thes
risks should be effectively managed in order to derive the utmos
of benefits and avoid disruption and/or catastrophic econom
consequences for the food industry and market participant
wellbeing.
In (food) economics, finance and marketing-management liter
ature, the utility concept (total satisfaction received from consum
ing a product/service) plays a crucial role in determining marke
participants’ benefit–risk trade-offs that drive economic phenom
ena. This utility is often derived from outcomes such as wealth
income, profit, selling price, among others. That is, the outcom
domain is a monetary one. Yet, in behavioural economicPlease cite this article in press as: Tijhuis, M.J., et al. Looking beyond borders
Nutrition. Food Chem. Toxicol. (2011), doi:10.1016/j.fct.2011.11.044behavioural finance, economic psychology, marketing and con
sumer behaviour literature, market participants may also deriv
utility from non-monetary outcomes by exposing a combinatio
of cognitive and affective behaviour.
The dominant paradigm in business economics on which dec
sion makers (e.g. farmer, food manufacturer, retailer, consume
rely in their benefit–risk trade-offs is the expected utility mode
This model is concerned with choices among risky prospects. Th
goal of a decision maker is the maximization of his/her expecte
utility. In the expected utility framework, the shape of the utilit
function is assumed to reflect a decision maker’s risk preferenc
Therefore, the expected subjective utility function of any prospec
reveals the individuals’ attitudes towards risk. There is a continu
ous stream of research on decision makers’ risk preferences i
the fields of food economics and marketing–finance that employ
expected utility models that are objective or normative, i.
assumption and establishment of norms implying the rationalit
principle in economic behaviour of market-participants: maxim
zation of their utility, by using time series and/or panel data fo
production, consumption, pricing levels of food products; and sub
jective, i.e. relaxing the rationality assumptions inherent in th
normative models by using survey- and experimental-based dat
gathering instruments involving psychometric constructs or lotter
ies. Both theoretical and empirical research accounts show tha
decision makers can be simultaneously risk-seeking and risk
averse in different domains, implying that risk preference is con
text-specific.
In the context of agribusiness and food markets, concerns abou
food safety, quality, and nutrition have persistently been present a
all levels of decision making (operational, tactical and strategic) b
food producers, manufacturers, commodity traders, retailers, an
consumers. However, business economic scholars are often con
fronted with conceptual and methodological challenges due t
the unobserved and multidimensional nature of human decisio
making process. That is, the actual behaviour of market partic
pants is not always consisted with the ‘‘true’’ level of risk that the
face.
Recent research in management sciences and decision analys
argued that by decoupling the benefit–risk trade-offs of decisio
makers into separate dimensions a more robust conceptualizatio
and prediction may be achieved. Specifically, market participant
have two kinds of evaluation systems on which perceived and/o
actual benefits of an investment or consumption object cognitivel
rely on: (a) utilitarian dimension of instrumentality and (b) a hedo
nic dimension. The first dimension refers to how useful or benefi
cial the investment or consumption action is. The secon
dimension of benefits refers to the experiential affect associate
with the investment and consumption. These two dimensions ar
neither mutually exclusive nor need to be evaluative consisten
Similarly, risk behaviour may be decoupled into the separat
dimension of risk attitude and risk perception. Risk attitude
formed by one’s predisposition to the content of the risk in a spe
cific market situation and reflects a decision-maker’s interpreta
tion of this risk content in a specific way, whereas risk perceptio
refers to the likelihood of one’s exposure to the risk content. Th
decoupling approach may serve as the basis for studying the dec
sion-making process of market participants regarding food safety
and nutrition-related issues, in the light of benefit–risk trade-off
Yet, one may recognize the challenges for operationalising such
framework, adapt it to specific decision contexts, and accountin
for its dynamics.
In conclusion, the study of market participants’ benefit–ris
trade-offs in business economics rely on the utility concep
Although the dominant paradigm in economics is the expecte
utility model that has a normative nature, the behavioural stud
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ere are various and different approaches and techniques to
sinesses economics to identify and evaluate the benefit–risk
de-offs on institutional or individual market participants. Yet,
ere is no single view to dominate the whole discipline. The
coupling of benefit–risk behaviour into separate components
at deal with both the utilitarian as well as hedonic aspects of
nefits and risks may offer more robust conceptualizations and
edictions for studying benefit–risk trade-offs in various highly
certain decision contexts entailed in the agribusiness and food
arkets.
. Benefit–risk analysis in Consumer Perception (Ueland et al., 2011)
Food and nutrition are central to the survival of human beings
well as to their well-being and quality of life. However, a ‘‘nutri-
nally perfect life’’ is not necessarily consistent with consumers’
lings of how a perfect life should be which again has implica-
















































688ths are partly the result of consumers’ perceptions of benefits and
ks with regard to food and nutrition and of the way consumers
de off between benefits and risks in order to maximize the out-
me they prefer. Thus, by incorporating the study of consumers’
rception of benefits and risks in a food and nutrition context,
ssible outcomes of food and nutrition measures can be better
derstood.
For consumers, benefit perception of food is usually more
portant than risk perception. The benefits are particularly re-
ed to the hedonic perspective; food should taste good, be plea-
rable and fulfil expectations to an enjoyable experience. Risks,
the other hand, are more often subject to conscious delibera-
ns and external factors, such as available information, media
verage and personal interest that contribute to consumers’ risk
rception.
Consumers’ perception of risks is associated with mortality
d morbidity and goes along two main dimensions related to;
e extent that the risk is unknown, and what are the conse-
ences of the risk. Food risks are not perceived to be as severe
are for instance risks associated with firearms or airplanes.
wever, some foods, particularly those that score high on the
known dimension, are perceived with trepidation by consum-
s. Conversely, foods that are perceived as risky are often foods
at are unfamiliar or produced by novel technologies. Further-
ore, foods that are (perceived to be) highly processed are con-
ered to be less desirable and more risky, than foods
rceived to have a low level of processing. The possibility to dis-
rn what the food product is made of, or what it is derived from,
ntributes to a feeling of safety and to lower risk perception
ong consumers.
There are ways to reduce perceived risk of foods for instance
rough familiarising the consumer with the food, or by adding
aracteristics that may be seen as benefits to the food product.
creasing healthiness and enhancing taste are factors that make
nsumers more willing to accept the product. Adding benefits to
roduct does not reduce the risk itself but reduces the consum-
s’ perception of the risk. Benefit and risk perception of foods
e in many cases inversely correlated: when something is per-
ived as being highly beneficial, it is correspondingly perceived
having low risk. However, slightly different paths are used in
e formation of these perceptions; benefit perception is based
heuristics and experience, while risk perception is largely the
sult of cognitive information processing.
Nutrition is one aspect belonging to food products that is nor-
ally not associated with hedonic benefits of foods. However,
trition is accepted as an essential part of consumers’ life, and
alth attributes of foods are perceived as benefits when diet con-
erations are important for the consumers. Consumers easilyease cite this article in press as: Tijhuis, M.J., et al. Looking beyond borders: Inte
utrition. Food Chem. Toxicol. (2011), doi:10.1016/j.fct.2011.11.044rceive risks belonging to malnutrition, both related to over-
d under-consumption of nutrients, but consumers’ may choose
t to pay attention to these risks.
In conclusion, in a food and nutrition setting it is important to
derstand which food attributes related to perceived and real
nefits and risks that influence food choice, in order to provide
r an optimal diet from both a health perspective as well as from
edonic perspective.
. Contemporary regulatory context for Food and Nutrition
sessment and management
The EU Food Safety legislation (http://ec.europa.eu/food/food/
odlaw/index_en.htm)(EU, 2000) is built around high food safety
ndards, of which the final aim is to protect the health of the con-
mers and to reduce the risks connected to unsafe food (van der
eulen and van der Velde, 2008).
The development of the requirements is the result of stratified
islative measures, often approved by incidents (food safety cri-
s consequent to foodborne diseases) rather than by a systematic
islative plan. Regulation EC/178/2002 is the General Food Law,
ntaining general provisions useful to orientate the interpreter
understanding the mechanisms and procedures to be followed
order to reduce risks related to unsafe food. The general princi-
es of food law may be considered the top of the ideal pyramid of
egulatory food control systems. Regulations and directives have
en formulated within this frame.
The aim of EU food policy is to assure a high level of food safety,
imal health, animal welfare and plant health within the Euro-
an market. In this sense, the General Food Law constitutes the
ain reference point of the EU food legislation. It applies to all
ges of the production, processing and distribution of food and
o to feed produced for, or fed to, food producing animals. More
detail, the General Food Law establishes the principles of risk
alysis in relation to food and establishes the structures and
echanisms for the scientific and technical evaluations which
e undertaken by the European Food Safety Authority (EFSA). As
exception of the general tendency to regulate risks rather than
nefits, it is worth mentioning the EFSA health claims procedure
der Regulation (EC) No 1924/2006, which plays a relevant role in
e regulation of the benefits. Nevertheless, also in this case, we
ay see that the final objective of regulating benefits turns into
e legislative intention to prevent risks, both connected to the
nctioning of the market and to the consumers’ protection, if we
nsider that the general objective of the Regulation is to ensure
e effective functioning of the internal market as regards nutrition
d health claims whilst providing a high level of consumer pro-
ction (EC, 2006).
Food law, and in particular measures relating to food safety
ve to be based on scientific expertise. The EU has developed its
n risk analysis principles in conformity with the International
ndards. Regulation EC/178/2002 establishes in EU law that the
ree phases of risk analysis (risk assessment, risk management
d risk communication) provide the basis for food law as appro-
iate to the measure under consideration. Therefore, the General
od Law states that scientific assessment of risk must be under-
ken in an independent, objective and transparent manner based
the best available science. Risk management is the process of
ighing policy alternatives in the light of results of a risk assess-
ent and, if required, selecting the appropriate actions necessary
prevent, reduce or eliminate the risk to ensure the high level
health protection determined as appropriate in the EU. In the
k management phase, the decision makers need to consider a
nge of information in addition to the scientific risk assessment.
ese include, for example, the feasibility of controlling a risk,
e most effective risk reduction actions depending on the partgrating best practices in benefit–risk analysis into the field of Food and
689 of the food supply chain where the problem occurs, the practical
690 arrangements needed, the socio-economic effects and the environ-
691 mental impact. Regulation EC/178/2002 establishes the principle
692 that risk management actions are not just based on a scientific
693 assessment of risk but also take into consideration a wide range
694 of other factors legitimate to the matter under consideration (see
695 http://ec.europa.eu/food/food/foodlaw/principles/index_en.htm).
696 In sum, at a legislative level we may observe that the main
697 objective is to regulate risks connected to unsafe food, rather than
698 benefits and the balance between risks and benefits. Risk manage-
699 ment is a procedure which involves legislative tools together with
700 scientific expertise. The choice to regulate risks rather than bene-
701 fits is deeply linked to the necessity to reduce the risks on the mar-
702 ket by defining the tasks of the European Commission, the
703 European Food Safety Authority (http://www.efsa.europa.eu) and
704 the national competent authorities in charge to implement at local
705 level the European provisions.
706 3. Commonalities and differences, and illustration in a case
707 study
708 This section contains some of the characteristics that the differ-
709 ent fields, described in the previous section, share in common and
710 in which they differ with respect to benefit–risk analysis.
711 The general settings in which benefit–risk analyses within the
712 different fields currently may take place are described in Table 1.
713 The general characteristics of integrated assessment of benefits
714 and risks within different fields are described in Table 2. In order
715 to illustrate the commonalities and differences, a conceptual case
716 example of replacing animal protein with environmentally more
717 sustainable dietary protein is presented in Table 3. The case exam-
718 ple described here is meant as an aid, to illustrate and characterize
719 the different fields that form this paper. The attributes in the ta-
720 bles, according to which benefit–risk analysis within the different
721 fields are described, are adapted from the framework applied for
722 characterizing approaches to benefit–risk analysis in the field of
723 environmental health in Pohjola et al. (2011a)) and explained in
724 Table 4.
725 In Section 3.1, general commonalities and differences are de-
726 scribed, taking the main points from Tables 1 and 2. Issues arising
727 from the illustrative case study in Table 3 are discussed in
728 Section 3.2.
729 3.1. General commonalities and differences
730 The purpose of benefit–risk management is to arrive at the opti-
731 mal decision, while accounting for all relevant issues. The purpose
732 of benefit–risk assessment is to provide the science-based informa-
733 tion on the integrated benefits and the risks to support in answer-
734 ing the benefit–risk management question, i.e. to contribute to
735 evidence-based decision making. The focus of benefit–risk analysis
736 in the different fields is
737 - Food and Nutrition: improving public health/preventing disease
738 by better food and nutrition and generating knowledge for food
739 improvement or innovation and general understanding.
740 - Medicines: curing, slowing or preventing disease by means of
741 medication and monitoring benefit–risk profiles of marketed
742 medicinal products with or without its impact on budget.
743 - Food Microbiology: preventing foodborne disease caused by
744 micro-organisms and generating knowledge for microbiological
745 product innovation.
746 - Environmental Health: preventing damage to health mediated
747 through the environment, possibly also reducing impact on
748 economy, society and environment.
749- Economics and Marketing–Finance: optimising public economic
750policies, corporate investment and marketing strategies.
751- Consumer Perception: stimulating good food choice by using
752insights in consumers’ perceptions, attitudes and behaviour
753relating to a particular case and by increasing acceptance
754through information, increasing familiarity, reducing uncer-
755tainty, and product optimization.
756
757The challenges of aggregating and weighing benefits and risks
758are shared by the different fields. Two issues coming up in this con-
759nection are the inclusion of multiple benefits and risks with differ-
760ent scopes, and the explicit inclusion of subjective information.
761Among the fields that are considered, assessments in Food and
762Nutrition, Food Microbiology, Medicines and Environmental Health
763focus predominantly at health/disease, mostly physical health/dis-
764ease (though several approaches in Environmental Health are open
765to also include other domains). Quantitative weighing of benefits
766and risks via DALYs or QALYs has been performed in Food and
767Nutrition, Food Microbiology, Environmental Health and in post-
768marketing modelling studies for Medicines. Mostly this is done
769within strict and relatively narrow bounds, e.g. focusing on the
770health effects of food compounds. In Economics and Marketing–Fi-
771nance as well as Consumer Perception, health is not the centre of
772attention. In the latter two, human perception and behaviour is
773an important topic of investigation, whereas the former four strive
774for more ‘objective’ health information. However, also there, the
775influence of perception and behaviour is acknowledged, at least to
776some degree, e.g. in the form of the placebo effect and compliance
777to prescriptions or advice. Qualitative comparison and use of expert
778judgment are part of all fields, but in differing degrees. For example,
779expert opinions/judgments in different phases have an important
780role in the progress of medicine benefit–risk analysis along the
781early stages of drug development. In Food and Nutrition, (expert)
782value statements are explicitly named only in comparison or com-
783bination of benefits and risks (e.g. qualitative comparison, and dis-
784ability weights). Non-expert value judgments are increasingly
785taken into account particularly in Environmental Health.
786Another notable issue relates to differences in the valuation of
787benefits and the acceptability of risks, both by consumers and
788managers. In Food and Nutrition and Food Microbiology, chemical,
789biochemical and microbiological risks are not accepted, i.e. food
790safety issues are minimised to such a low level that risks are virtu-
791ally absent (see also Section 2.7). Especially Food Microbiology is
792illustrative of the important role of ‘risk’ in public health. In con-
793trast, in many approaches to Environmental Health and in Medi-
794cines, some risk is accepted for a greater benefit. In Medicines,
795risk, in the form of adverse drug reactions, is accepted for the
796greater benefit of recovery or of alleviation of symptoms. Also, by
797observing the common everyday practices, some degree of risk
798coming from the environment in the form of traffic, energy produc-
799tion, radiation, disinfection, etc. can be considered as accepted in
800order to meet the needs of modern society. However, the percep-
801tions of such risks may vary significantly among policy makers
802and the public, and the differing perceptions may not always be
803backed up with well-reasoned knowledge. Moreover, in Economics
804and Marketing–Finance and Consumer Perception, (high) risks can
805be accepted if the expected benefits are higher and at least some
806degree of risk is accepted as necessary to bring about benefits in
807general. Some differences with respect to the degree in which risk
808is accepted and benefit is valued are illustrated in Fig. 2. With re-
809spect to Food and Nutrition, there appears to be a discrepancy:
810risks brought about by unfavourable nutritional quality and/or
811quantity of the diet (i.e. unbalanced intake of nutrients and foods
812resulting in deficiencies and/or chronic disease), are more readily
813accepted (as voluntary, right to choose) both by consumers and
814policy makers.
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Table 1
Current general setting for benefit–risk analysis within different fields.
Attributea Food and Nutrition Medicines Food Microbiology Environmental Health Economics and Marketing–Finance Consumer Perception
Management question What is the optimal
decision for public health,
where and how can the
largest net population
health gains be realised,




- policy for fortification
- food processing
methods
- introduction of novel
foods
What is the optimal decision for
public health, with respect to
- drug safety
- drug efficacy
- drug safety monitoring and
management
- drug benefit–risk balance
- eligible patient populations
What is the optimal
decision for public
health, with respect to
microbial food safety and




What is the optimal decision for
public health when focusing on
environmentally mediated direct
and indirect health impacts? Can
be considered in the context of
other issues such as
- economic impacts
- equity and social well-being
impacts
- impacts to the environment
What is the optimal utility that
market participants derive from
outcomes based on benefit–risk
trade-offs such as production, costs,
sales, or consumption of a food
product?
Other issues to be considered:
- cognitive vs. affective decision
making
- risk attitudes (RA) and risk per-
ceptions (RP) formation
- drivers of RA and RP (e.g. trust,
knowledge)
- utilitarian vs. hedonic benefits/
gains
What is the optimal
decision from an
acceptance perspective

























Policy makers, industry, citizens
(decisions), scientists, industry,
commerce, in some approachesb,




Producers, marketers, policy makers,
consumers (decisions), financial
analysts (assessment of technical
feasibility), marketers (assessment of
economic feasibility), industry















Ranges from separate to
intertwined. Also depends on the






Approachesb range from strictly
separate to deeply intertwined
Approaches range from aggregate to
disaggregate. They involve ad hoc
self-assessment in decision
situations by consumers. More
systematic assessment, often by










a Attributes are explained in Table 4 and adapted from the framework applied for characterizing approaches to benefit–risk analysis in the field of environmental health in Pohjola et al. (2011a).
























































































General characteristics of integrated assessment of benefits and risks within different fields.
Attributea Food and Nutrition Medicines omics and Marketing–
ce
Consumer Perception
Assessment question - What are the inte-
grated health benefits
and risks of (a change
in) consumption of a
food or food compo-
nent in a particular
population? What is
the current state of
knowledge regarding
a health issue?
- What is the pre-registra
benefit profile of a med
- What is the post-re
risk–benefit profile of a
medicine?
- What is the cost-effect
a health technology in
population?
hat drives market par-
icipants’ decision mak-
g process and hence
heir actual behaviour
nder risk?
What drives food pro-
ucers’/farmers’ risk–
enefits trade-offs, e.g.
egarding the use of opti-






- What are the charac-
teristics of food items
that influence con-
sumers’ perceptions
of benefits and risks,
attitudes and
reactions?
- What is/are the target
population(s)?
Measurements of risk Increased disease risk
from food or food
component















Reduced disease risk or
improved health state
from food or food
component
Disease treated, disease pro
stopped or slowed by medi




ities in which market
cipants may be engaged





perceived benefits such as
liking, and feeling good




Answer - Quantified benefits
and risks
- Comparison with





- Quantified benefit and r
- Integrated measures




nalyses of the dynamics
f decision making
rocess.
omparison of actual vs.
erceived behavioural
utcomes
ccounting for the influ-
nce of the unobserved
eterogeneity on market
articipants’ behaviour




ay explain several pat-
erns/paradoxes in eco-
omic behaviours











































































































What are the direct and indirect
environmentally mediated health
impacts of e.g.




- in principle anything
- Approaches vary significantly in






















Introduction of new and
emerging pathogens
Risk of compromised health due to
something. Non-health risks caused


















Expected health benefits due to
something. Non-health benefits

















- Estimates of risks and benefits.
- Comparisons and/or aggregated
measures. Mostly quantitative,
but qualitative also possible.
Approaches vary greatly in
breadth of inclusion as well
means of weighing and/or
integration.
- Mostly health risk(s) considered
in the context of other factors:
e.g. other risks, benefits.
- Comparison of impacts of differ-




















815The field of Medicines stands out by being aimed at a single
816product or technology, which is tested within a controlled environ-
817ment (pre-registration); the situation in ‘real life’ (e.g. interference
818from other medication or from food, low compliance) can be ob-
819served only after market approval. In all phases of the life of a med-
820icine, the benefit–risk balance can be different. The benefit–risk
821balance can also change during the life of an individual. Within
822Medicines, as well as Consumer Perception, there is a stronger indi-
823vidual basis than in the other areas.
824Notable in Environmental Health is the development towards
825more interaction between all those who are in some way related
826to the process (assessors, managers, industry, NGO’s, and citizens)
827and to let actual problems drive analyses. In Food and Nutrition,
828increasing engagement between assessors and managers is recog-
829nized to be valuable, but presently there is virtually no role for
830stakeholders in assessment.
8313.2. Illustrative case example
832The case example presented here (Table 3) to illustrate Section
8333.1 from a practical viewpoint deals with dietary protein sources,
834in particular the effect of replacing less sustainable sources with
835more sustainable sources. Protein and the amino acids that build
836protein are important, as they form the body’s system of structural
837and functional elements that exchange nitrogen with the environ-
838ment and have many other functions (Millward et al., 2008; WHO,
8392007). Converting plant protein sources into animal protein
840sources is relatively inefficient and negatively affects the ecosys-
841tem when applied on a large scale (FAO, 2006). With the increasing
842world population and the net increased affluence, the consumption
843of animal protein is increasing. Without policy action, the ecosys-
844tem is overly pressured and food security is endangered. Alterna-
845tive protein sources, with less impact on the ecosystem, are
846known. They include plant sources, algae, insects and cultured
847meat. The aim of the benefit–risk assessment is to support well-in-
848formed policy making with respect to a protein transition by pro-
849viding the best available science.
850From Table 3 it can be seen that the fields of Food and Nutrition,
851Medicines and Food Microbiology have a rather tight focus,
852whereas the fields of Environmental Health, Economics and Mar-
853keting–Finance and Consumer Perception apply broader scopes in
854their assessments. Especially in the latter two the effect on
855health/disease is only one of many considerations in the broader
856implications that a shift in focus from animal to plant protein
857has. Table 3 also shows the different types of measurements and
858approaches used to answer the assessment question.
859Furthermore, the case study shows that a successful protein
860transition, even when a net benefit is supported in terms of health
861and sustainability, co-depends on consumer perceptions and ac-
862tions in terms of its actual realization. Sustainability and health
863are, for a large segment of consumers, less important drivers of food
864choice than e.g. the liking of animal protein rich products. For alter-
865natives to be accepted, some criteria will have to be considered,
866among others: taste, expense, use of technology/naturalness, and
867trust. Marketing and communication strategies will be essential
868in creating acceptance. However, if long-term net benefit is to be
869achieved, there is also an essential role for the authorities in ac-
870tively ‘making the healthy and sustainable choice the easy choice’
871and implementing necessary regulations towards food industry.
872From the regulatory point of view, the eventual choice to shift
873to dietary protein sources that are more sustainable than the cur-
874rent animal products should not constitute a further burden for the
875legislator. In case new products are being introduced, the general
876framework to regulate risks connected to these products remains
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Table 3
Illustration of the commonalities and differences between fields by means of a conceptual case example – replacing animal protein sources with more environmentally sustainable protein sources.*





- What is the net public health
consequence of promoting
and facilitating the con-
sumption of sustainable pro-
tein sources?
- Do certain subgroups require
special attention?





- Do certain subgroups re
special attention?
ow can an effective and
ficient economic deci-
on be made regarding
e shift of food produc-
n focusing on plant
otein methods?
ow can such food items
marketed effectively?
- How can food industry
managers and policy
makers assess, predict,




success of a shift in








- Higher dietary contribution
of old and new plant foods
and lower dietary contribu-
tion of meat and dairy.
- ‘‘new’’ dietary source, e.g.
insects; In differing degrees
(scenarios)?Special attention
for those with special needs,
such as children
What is the benefit–risk ba
of substituting animal prote
with alternative protein
sources?
- Who benefit from w
positive health effects?
- Who are at risk from w
adverse health outcome















In what way may a shift in
focus from animal to plant
protein be acceptable and
for whom?
How is the topic
understood?
What are preferable




- Nutritional status, e.g.
reduced iron, vitamin B12,
calcium;
- Morbidity and mortality, e.g.
increase in allergy; e.g. soy,
lupin, other new protein;
insect poisons
Morbidity and mortality; e.

















- Nutritional status, e.g.
reduced saturated fatty
acids, increased vitamin C,
folate, phytonutrients
- Morbidity and mortality, e.g.
reduced obesity, CVD
Morbidity and mortality, e.g
reduced obesity, reduced CV
influence of reduced protein










Answer - Incidence of nutritional defi-
ciencies and improved nutri-
tional status




CVD and other ben
Number needed to tre
achieve a single bene
outcome.
- Predicted risks. Nu












e aim to promote/pro-
ce socially, economi-




- Identification of driv-
ers for acceptance and
how they should be
presented for the
consumers



























































































- What is the net public health con-
sequence of promoting and facili-
tating the consumption of
sustainable protein sources?
- Do certain subgroups require spe-
cial attention?
- What is the optimal way
of reducing the environ-























- the weighted effects when substi-
tuting animal proteins with alter-
native protein sources, with
respect to
- microbiological health risks/ben-
efits of alternative protein
sources?
- increased/reduced exposure to
foodborne pathogens?
- food safety of protein from
microorganisms (single cell pro-
tein) for human consumption?
- risk of new and emerging patho-
gens from new food production
processes and/or alternative pro-
tein sources?
What is the health impact of
changing animal protein to
other protein sources? Both
direct (via food) and indirect




impacts should be known
for overall conclusions, but
they may be assessed
elsewhere. Options may also
be assessed according to
their environmental
(ecological) impacts in order
















- Morbidity, and mortality.
- Increased exposure to pathogens
during storage of plant foods/
insects e.g. mycotoxins, grain
molds, spoilage organisms, food-
borne pathogens.
- Increased exposure or introduc-
tion of new pathogens
Health impacts of diet
change, actual vs
anticipated diet changes,
pollutants in diet, possible










- Reduced morbidity and mortality
due to decreased exposure to
foodborne pathogens.
- Microorganisms as an alternative
source of protein/food
- Health impacts of diet
change.
- Also non-health benefits















- Incidence and morbidity of food-
borne disease e.g. using DALY.
- Health benefits of increased
access to alternative source of
protein (‘‘single cell proteins’’,
SCP)
- Incidences of health
impacts, possibly sum-
marised as e.g. DALYs.
- Ecological and other
impacts presented and
discussed. Comparison
of health and other















8794. Opportunities for Food and Nutrition benefit–risk analysis
880In this section we discuss how benefit–risk analysis for food and
881nutrition may improve from looking at other research areas. A
882number of issues that require further attention in Food and Nutri-
883tion have been identified (Tijhuis et al., 2011). To name some key
884issues:
885Paradigm. In the contemporary benefit–risk analysis paradigm
886(Fig. 1), assessment and management are marked entities. Commu-
887nication and some degree of interaction, though acknowledged,
888may not currently receive the attention they deserve, both within
889and between the analysis components. In addition, management of
890public health in Food and Nutrition is currently still very much fo-
891cused on risk and aimed at identifying numbers below which in-
892take is presumed to be safe.
893Data. The arms of the benefit–risk assessment paradigm are not
894symmetric; they currently serve different goals (i.e. to demonstrate
895presence of benefit and absence of risk), they are built on different
896methodologies, they are rooted in different research traditions, etc.
897For a benefit–risk analysis in Food and Nutrition it is essential that
898quantitative data on beneficial and adverse effects are available,
899covering the relevant exposure and target population. For many
900foods and ingredients this is currently not available. A fundamental
901difficulty in this is the translation of dose and effect found in ani-
902mal studies to the human situation. Apart from this species issue,
903lack of dose–response data is also a problem for human studies.
904There are several possible reasons for this, not always easily solv-
905able: performance of studies in humans is expensive, is ethically
906not acceptable or scientists are not used to quantifying or present-
907ing dose–response information; also, in benefit assessment the le-
908gal situation is new.
909Context and implementation. Besides issues relating to assess-
910ment and comparison of benefits and risks, there is currently often
911no explicit consideration of which benefits and risks should be con-
912sidered in different contexts and why; and whether only health
913risks and benefits induced by foods and food ingredients are suffi-
914cient in light of the practical uses of the benefit–risk analysis re-
915sults. With respect to outcomes in the form of advice, there is a
916discrepancy between results from assessment of benefits and risks
917in the form of advice, and consumers’ behaviour. Input of the pub-
918lic and other more specified stakeholders into assessment and
919management, to drive the analysis or to find solutions, is currently
920not common.
921Below, these issues are addressed further in the form of con-
922cepts and practices from other fields that may be incorporated
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blease cite this article in press as: Tijhuis, M.J., et al. Looking beyond borders: Inte
utrition. Food Chem. Toxicol. (2011), doi:10.1016/j.fct.2011.11.044.1. Increased engagement and communication between assessors,
nagers, and stakeholders
Thus far, benefit–risk analysis in Food and Nutrition has been
ilding on (the clearly demarcated) assessment and management,
d virtually no role has been provided for stakeholders in these
ocesses. However, the experiences from other fields indicate that
ore intimate interaction between assessors, managers, and stake-
lders is essential for effective implementation of existing and
ailable knowledge. This would take form in assessors, managers,
d stakeholders in the field of Food and Nutrition each having
eir specific roles and responsibilities while engaging in the
ared process of developing and applying knowledge (Fig. 3).
creased engagement can enhance e.g. clarity of the relevance
assessment questions and applicability of assessment results
well as acceptance of the outcomes of their practical

































Explanation of the attributes applied in Tables 1–3.
Attribute Explanati
Management question The publi
Main problem owners and stakeholders Those res
Assessment-management interaction The natu
Assessment question The issue
Measurements of risk The types
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2 December 2011Communication is (increasingly more) important between a
those involved in the analysis: next to a role for professional com
munication specialists to address the stakeholders/general publi
the assessors and managers could benefit from increased commu
nicational skills between and amongst them, to result in a share
understanding of science and values (Fig. 3). Standardized form
formats, practices, and procedures can be helpful in facilitatin
communication e.g. by allowing participants in the analysis to fo
cus on the content instead of the format or by making the genera
public more familiar with risk and benefit information. Howeve
the standardized formats and practices should not be made to
strict and coercive, yet be flexible enough so that they can adap
to changing needs and contexts. For example, the informatio
structure of Opasnet, a web-workspace for conducting open assess
ments, provides a universal information structure that is applicabl
















Fig. 2. Acceptance of risk and valuation of benefit within the different fields. Loca
Fields with great variation regarding acceptance of risks and valuation of benefitsPlease cite this article in press as: Tijhuis, M.J., et al. Looking beyond borders
Nutrition. Food Chem. Toxicol. (2011), doi:10.1016/j.fct.2011.11.044formatting of the actual substance of the descriptions (Pohjol
et al., 2011b). Another example is the web-based QALIBRA sof
ware for quantitative benefit–risk assessment in foods. The sof
ware is web-based and free to users after completing a sho
online training session (www.qalibra.eu). It provides a consisten
conceptual framework to help think about, organise and execut
risk–benefit assessment, and optional sharing and discussion o
assessments and data with other users.
4.1.2. More pragmatic problem-oriented framing of assessment
One of the aspects that can be enhanced by increased engage
ment, as also mentioned above, is framing of assessments and for
mulation of assessment questions to better serve the practica
needs of those who (are intended to) use the assessment result
in practice. Although purely curiosity-driven question setting
defendable in traditional science, assessments may better b
on
c issue that is to be addressed
ponsible for or involved in the analysis
re of the relationship between management and assessment
that is to be addressed and requires an answer
of exposure and effect measurements used to characterize the risks
of exposure and effect measurements used to characterize the benefits
of information produced to answer the question
















known, controllable, habit, 
natural, unobservable
of each node represents a stereotypical approach to benefit–risk analysis within a fiel
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1050nsidered as processes of applying scientific means and knowl-
ge for practical problem solving, and thus adopting a demand-
iven pragmatic approach. In order to achieve this, incorporation
decision makers as well as stakeholders, e.g. consumers and
dustry, in analysis is necessary.
Along this line, in most cases food products that consumers
tually ingest (whole foods) may be more relevant objects of ben-
t–risk than mere isolated food ingredients or substances in food.
so, in addition to looking at only the health risks or benefits of
e food itself, the rest of the food pattern should receive some
tention to be practically useful.
.3. Accepting some risk: inevitable inter-linkage of risk and benefit
Risk is omnipresent, but it should be realised that so is benefit.
sk and benefit go together. Policy aimed at the combination of
inimizing risk and maximizing benefit may result in a net higher
nefit for public health than policy aimed at minimizing risk only
. 3. A new framework for benefit–risk analysis emphasizing increased commu-
ation and engagement. Creation of shared understanding based on both science
d values is at the core of the joint knowledge process. Communication is essential
ring the whole process of benefit–risk analysis. Stakeholders are explicitly




























1077itrisk. Or, from a positive perspective, it means acceptance of tak-
g benefit into explicit consideration. This will not only result in
ore informed public health decisions, but also create more public
pport and understanding of the broader picture within which
cisions are made. Where the optimum for health lies needs to
assessed on a case by case basis, addressing also the needs
d context of each specific case (see Section 4.3).
.4. Pre- and post-market analysis of benefits and risk of food
oducts
Based on the experiences from the medical area, both pre- and
st-market analyses could be required for certain food products.
re-market assessment may be conducted by the producer of rel-
ant foods or food ingredients (and evaluated by independent
thorities), prior to market introduction, to address benefits and
ks according to the current knowledge level. A post-market anal-
is (also termed ‘postlaunch monitoring’ (de Jong et al., 2007) and
st-market monitoring’ (Hepburn et al., 2008) would engage all
keholders, in particular authorities, with inputs from consumer
ganisations, science and industry. Post-market analyses may be
ggered whenever new important evidence is gained, thus result-
g in a follow-up over years. (Passive) surveillance systems can
rm the first step in identifying signals of potentially unknown
ks. In addition, surveillance systems can also follow up on
neficial physiological effects of food or food ingredients (de Jong
al., 2007) and can be used for evaluation purposes: did a benefit–
k advice or decision have effect? Such post-market effectivenessease cite this article in press as: Tijhuis, M.J., et al. Looking beyond borders: Inte
utrition. Food Chem. Toxicol. (2011), doi:10.1016/j.fct.2011.11.044onitoring may form an elegant and desirable addition to the
alth claims area (de Jong et al., 2007; Hepburn et al., 2008). This
st market effectiveness monitoring could be part of a dynamic
d pro-active management plan where there is feedback between
blic health efficacy, management and manufacturers.
. Data
.1. Explicit communication of the assessment purpose, input and
tput
If benefit–risk analysis intends to achieve its goals of improving
blic health through the realized net benefits of consuming food
oducts, it needs to produce explicit messages of their benefits
d risks as well as the factors that influence them. There is ongo-
g discussion regarding the common currencies being developed
d applied for aggregating and communicating multifaceted
alth and other outcomes (Tijhuis et al., 2011). One area of re-
arch that is still open is how to better take account of above aver-
e health states within the aggregated measures, e.g. quality
ights. Also, the long-accepted definition of health (WHO,
48) is now increasingly being debated to include the ability to
apt (Anonymous, 2009; Huber et al., 2011).
Often it is advisable, if possible, to use more than one outcome
easure, for example DALY and cost effectiveness. This will also
ow the broader perspective that surrounds each case, and may
event or lower a false sense of security that quantification of
mplex issues in one measure may give. Finding optimal (combi-
tions of) aggregated measures is important, however, it may be
en more important to consider how to best explicate the essen-
l aspects of the information produced in the analysis in different
uations and contexts.
It needs to be realized that all models are inherently false if the
al is to 100% reflect reality; they can be useful, however, when
ed and interpreted in the right way. Some input into the models
surrounded by more uncertainty than other. This can be at least
aluated by sensitivity analyses or value of information analysis
altelli and Annoni, 2010; Tuomisto et al., 2004). The uncertainties
n be made explicit. Some uncertainties may not be very impor-
nt for the outcome. Uncertainty is more important for the param-
ers that drive the outcome, or in other words: that form the basis
r the ultimate decision. It also needs to be realized that different
pertises are involved and required in creating the output, such as
athematicians, nutritionists, toxicologists, medical doctors, etc.
creased interaction between disciplines and domains will
timize the modeling, the input the models require and their
terpretation.
.2. More human (dose–response) data and more efficient use of
man data
Human data are more valuable than animal data for assessing
th benefits and risks, as there is no need to extrapolate/translate
se, effects and physiological differences. Human data, however,
e also less available: they are often more expensive and more dif-
ult (sometimes impossible) to obtain than animal data. On two
counts, however, benefit–risk analysis could benefit relatively
sily from data that already exists or is conveniently available.
Firstly, researchers often can present more quantitative data in
eir publications. For example, when presenting a group risk cov-
ing a range of exposures (e.g. a quartile), information on expo-
re and its variation can be included.
Secondly, human data can also be obtained in the post-market
ase for products for human use (see also Section 4.1). Obtaining
ta in the post-market phase has advantages. It allows real-life
formation to be incorporated into the assessment, such as
mpliance, compensation behaviour and real-life effect size. Also,










































































M.J. Tijhuis et al. / Food and Chemical Toxicology xxx (2011) xxx–xxx 15
FCT 6275 No. of Pages 18, Model 5G
2 December 2011Experience in Medicines has also shown limitations of post-mar
keting surveillance, however, such as reporting bias and selectio
bias. In the social sciences there is a new trend to actively let con
sumers participate in data generation, in the form of creating pan
els to obtain research data. It may be informative to follow th
development.
As the availability of applicable data is hampering the use o
benefit–risk analysis in Food and Nutrition, it may be relevant t
establish a database on benefit and risk data and research to pro
mote and coordinate its further development. However, selectiv
reporting should be prevented and thus a system of registratio



































































1188knowledge (Singh, 2011) to the extent that food industry has
1189//database) would have to be considered.
4.2.3. Distinguishing physiologically different populations within the
consumer population
As in Medicines, where the dynamics of the benefit–risk profil
throughout the life cycle is recognized, some researchers in Foo
and Nutrition are also developing towards a more inter- and in
tra-individualised approach. For example, in the window of benefi
approach, inter- and intra-individual variation is explicitly take
into account (Tijhuis et al., 2011). One disadvantage of populatio
health measures is that its effects are not always visible for individ
uals (prevention paradox). This could be overcome by a more ind
vidualised approach, which may have an additional psychologica
advantage of increased compliance. Difficulty is that the more
subgroup approaches the individual (i.e., n = 1), the more difficu
it becomes to show the effectiveness of a measure, using trad
tional statistical methods.
In some cases, benefits and risks apply to different populatio
segments. For example, by fortifying a staple food with folic acid
the children of women in the 1st trimester of pregnancy (the targe
group) will benefit from the risk reduction of neural tube defect
but other groups may also be affected (and not always favorably
(Hoekstra et al., 2008). Both an opportunity and a challenge lie i
specifically targeting the population groups that benefit most from
the food product.
4.2.4. Explicit consideration of value judgments in assessment
Value judgments, based e.g. on opinions, interpretations an
perceptions, have an important influence on decision making an
behaviour e.g. by food safety managers, food producers, marketer
and consumers. Therefore, identification and understanding of th
values that drive e.g. decisions of managers and behaviour of con
sumers need to be explicitly taken into account in systemat
assessment alongside scientific facts. This is essential for th
assessments to serve the practical needs of decision making. Th
is not to say that subjective value judgment could replace system
atically obtained research-based data and information in assess
ment (though assumptions, choices and interpretations ar



























1204dtative data, and the use of assessment results is subsequentl
guided by subjective opinions in policy making). But it can comple
ment scientific knowledge by making it more coherent, relevan
and applicable. For example, in the context of the case study (Tabl
3), a good benefit–risk assessment must systematically conside
the differing value judgments regarding e.g. the importance o
environmental protection, biodiversity, human health, persona
preferences about different foods, and cultural traditions that re
late to the issue of replacing animal protein with protein from
other sources in the diet. Failing to do so would likely result i
assessment outputs that are of little value in practical decisio
making. Value judgments are thus relevant and valuable input t
the science-based assessments as parts of effective benefit–ris
analysis.Please cite this article in press as: Tijhuis, M.J., et al. Looking beyond borders
Nutrition. Food Chem. Toxicol. (2011), doi:10.1016/j.fct.2011.11.0444.3. Context
4.3.1. Integration of multiple benefits and risks from multiple domain
Integration of multiple benefits and risks from multiple do
mains is an essential means for achieving enhanced applicabilit
of assessment results. Most often, a reductionist approach to ben
efit–risk analysis, focusing on narrowly bound problems, is no
adequate for serving practical real needs that do not obey disciplin
ary boundaries. Therefore, assessment and management should a
low for broad integration of both benefits and risks from multipl
domains, according to needs. By taking a holistic view of benefit
risk analysis at an early stage, decisions on which scientific area
should be included in the benefit–risk analysis will focus th
assessments. Not all other factors can be integrated into a commo
measure and aspects of health may remain in the focus of the pro
cess. However, they can be placed within a reasonable context, o
bigger picture, provided by the other aspects to be considered. Fo
example, benefit–risk assessment on fish consumption can show
that benefits prevail over risks, but consideration of sustainabilit
issues or consumer preferences may steer the analysis toward
inclusion of farmed fish raised on sustainable feed or alternativ
non-fish sources.
The importance of integration and contextualization is als
illustrated by the case study in Section 3.2. In the field of Foo
and Nutrition, dealing mostly with health, it can be quite relevan
to consider also consumer perception and behaviour, ethics, env
ronment, industry interests, etc. It should be noted that the rele
vance of context is already part of the principles of Food Law a
‘‘other legitimate factors’’ http://ec.europa.eu/food/food/foodlaw
principles/index_en.htm, making room for consideration also o
benefits. However, good documenting of the factors and practice
to incorporate them are still lacking.
4.3.2. Explicit recognition of the impact of consumer beliefs, opinion
views, perceptions, and attitudes on behaviour
Consumers are an essential stakeholder group regarding foo
and nutrition. In the process of benefit–risk analysis of Food an
Nutrition, it needs to be taken into account in what direction an
to what extent food and nutrition aspects may influence consume
behaviour. This includes studies on human decision making, o
behaviour of market segments and on benefit–risk tradeoffs i
these groups. Alongside benefit–risk assessment on a physiologica
level, consumer characteristics such as perceptions or values ca
be measured in order to correct for differences between consumer
or target groups in how they behave with respect to the problem
For example, in the case of monosodium glutamate (MSG), con
cerns by consumers and consumer groups about MSG consumptio
(Freeman, 2006; Williams and Woessner, 2009), influenced b
commonly available non-scientific information, override scientifibegun reducing or removing MSG from their products (http:
www.toro.no/index.php?mapping=344; http://www.unilever.com
vn/brands/foodbrands/knorr/index.aspx). Whether or not thNutrition research results, recognition of its existence and under
standing of its basis and impacts is important in assessment as we
as decision making by food safety managers, consumers, produc
ers, marketers and other stakeholders. Consumer studies ca
qualitatively and quantitatively assess consumers’ complianc
with advice and why benefits and risks are acted upon in differen
ways, both cognitively and unconsciously. The data thus provide
can be used as feedback in the benefit–risk analysis, to overcom
the difficulties associated with the traditional science-decision
communication approach. Just as a hazard is not a risk until ther
is exposure, a food is not healthy until it’s eaten. An important contr
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trition is particularly related to how to implement measures to
hieve the best effects. Identification of relevant target groups
d formulating communication strategies that work, are major
pects that could benefit the goals of benefit–risk analysis in food
d nutrition. From a management perspective, taking consumers’
w-points into account is relevant in the implementation phase
en the aim of the benefit–risk analysis is to provide advice,
rections or action plans. Specifically: in case consumer’s view-
ints are not in conformity with current scientific insights, risk
anagers should strive for means of an appropriate consumer
formation and education.
.3. Segmenting market participants behaviour
Differentiation of sub-groups can take place in terms of physio-
ical characteristics, as addressed before, but also in terms of
eir cultural, cognitive and behavioural characteristics.
The segmentation criteria for grouping the behaviour of market
rticipants depending on whether the food offering is aiming to
ach the end-user (e.g. consumer) or another business are differ-
t. The more typical criteria for segmenting prospects at a corpo-
te business level usually entail the industry type, the size of the
rporation, e.g. in terms of revenues or employees, time-related
tors, access to competitive offerings, and the need for custom-
tion, among others. The criteria that are often used to group
e behaviour of individual market participants (e.g. consumers)
ay include demographics, cultural-, economic-, religion-related,
cial-status, accessibility to food offerings, and avocation-related
terests, among others. Yet, once the identification of specific seg-
ents has been achieved, there is a series of subtle influences on
e buying behaviour such as the beliefs, views, concerns, atti-
des, perceptions, information needs, brand awareness, and com-
itment to specific values and business operations of market
rticipants. That is, a series of unobservable (e.g. latent) factors
ay influence the purchasing behaviour and/or decisions of differ-
t segments of food producers, wholesalers, retailers, managers,
d consumers. Moreover, the differing preferences of market par-
ipants that are attributable to their heterogeneous desires and
rying wants may be driven by several unobservable factors often
ferred in the academic literature as behavioural anomalies, such
humans’ personality traits (e.g. need for cognition, ambiguity,
ed for certainty, risk-aversion, loss-aversion, myopia, overconfi-
nce) or heuristics (i.e., rules of thumb) that lead people to find
ings out for themselves, usually by trial and error.
The consideration of a heterogeneous food market as a number
smaller homogenous food markets, highlights the diversity in
arket participants attitudes, perceptions and preferences and
eir driving forces. This view reflects the market-orientation of
e food industry. Such an orientation is essential if segmentation
market participants’ behaviour in the agribusiness and food mar-
ts may be used as one of building blocks of effective food and
trition policy-making and marketing-management planning.
Conclusions
The BEPRARIBEAN project has looked into benefit–risk analysis
thin six different, but somewhat interrelated, scientific fields.
e main findings of the project are described in the previous sec-
ns, particularly in the form of the key messages in the section
pportunities for food and nutrition benefit–risk analysis’.
While looking into benefit–risk analysis from different scientific
rspectives we realized that different fields are facing similar prob-
s. All fields struggle with the challenges of aggregation, weigh-
g, and comparison of multiple benefits and risks. This stresses
e need for an interdisciplinary approach and mutual learning.



















ease cite this article in press as: Tijhuis, M.J., et al. Looking beyond borders: Inte
utrition. Food Chem. Toxicol. (2011), doi:10.1016/j.fct.2011.11.044k is accepted (Fig. 2). Consumer and marketing sciences could
e useful insight in the psychological mechanisms behind this
d give advice in how to target specific groups or how to put risk
rceptions into perspective. Stakeholder participation is increas-
gly valued as important, thereby granting it a position in the ben-
t–risk analysis-triad next to assessment and management (Fig. 3).
creasing interaction between the three is essential for making pol-
decisions addressing real public health issues, using the best
ailable scientific data on diet-health relations. We want to
phasize again that interaction can and should take place without
ch losing its own responsibilities, roles and interests. The tiered
proach and transparency in assessment proposed for the Food
d Nutrition field (Tijhuis et al., 2011) is one way to support this.
Altogether, the key messages suggest that benefit–risk analysis
Food and Nutrition should be considered as a joint process
ere the experts, professional decision makers, as well as con-
mers and other stakeholders come together to create shared
derstanding (Fig. 3). In this, different domains of benefits and
ks are explicitly considered, as are their greatest net benefits
king subgroups into account). Focusing on food safety and not
dressing food benefits is a risk management decision just as
uch as accepting some risk in order to achieve more benefits.
her way, both policy makers and consumers should let go of
e artificial line between risk coming from chemicals and micro-
ganisms in the diet (captured in regulation for consumer protec-
n) and risk coming from a bad quality and quantity of the diet
ptured in dietary advice for consumer protection). In the end,
r both situations, the result is disease and burden to society; as
e former is currently relatively well taken care of, the latter cur-
ntly has much larger impact on public health and resources (Tij-
is et al., 2011; UN, 2011; van Kreijl et al., 2006).
The identification of several key messages that describe how
od and Nutrition benefit–risk analysis, as well as benefit–risk
alysis in general, should be practiced is not an end in itself.
ther, it gives guidance for developing and implementing such
actices in order to make this vision a reality. This work will re-
ire further development of the systems and tools started in pre-
us projects and adoption of new methods, tools, and data
urces to support the improved benefit–risk analysis practices.
1306ntributions are required from all relevant actors in the analysis
1307order to promote the realization of improved benefit–risk anal-
1308is. Regulatory frameworks may need to be adjusted to allow and
1309pport the new contexts and practices of analysis. Managers may
1310ed to adopt a more active role as participants in knowledge cre-
1311ion and allow for broader involvement of other participants in
1312e analysis. Assessors also need to adapt their attitudes towards
1313nsidering themselves in the role of facilitating the development
1314shared understanding, not only among experts, but also among
1315anagers and stakeholders.
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